QuidelOrtho Corporation (QDEL) has a negative trailing P/E of -0.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 8.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -115.84%, forward earnings yield 12.27%. PEG 0.85 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 43/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -50.7 | -0.38 | 3.49 | 3.66 | - |
| 2017 | -183.6 | 4.28 | 6.60 | 5.40 | - |
| 2018 | 28.0 | -0.03 | 4.88 | 3.98 | - |
| 2019 | 42.0 | 18.29 | 5.48 | 5.73 | - |
| 2020 | 9.3 | 0.01 | 5.68 | 4.55 | - |
| 2021 | 8.1 | -0.62 | 2.94 | 3.34 | - |
| 2023 | 8.9 | -0.21 | 0.99 | 1.49 | - |
| 2023 | -487.4 | 4.80 | 0.98 | 1.64 | - |
| 2024 | -1.4 | 0.00 | 0.99 | 1.06 | - |
| 2025 | -1.8 | 0.04 | 1.03 | 0.73 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.42 | $191.6M | $-13.81M | -7.2% |
| 2017 | $-0.24 | $277.74M | $-8.17M | -2.9% |
| 2018 | $1.74 | $522.29M | $74.18M | 14.2% |
| 2019 | $1.73 | $534.89M | $72.92M | 13.6% |
| 2020 | $18.60 | $1.66B | $810.29M | 48.8% |
| 2021 | $16.43 | $1.7B | $704.2M | 41.5% |
| 2022 | $9.56 | $3.27B | $548.7M | 16.8% |
| 2023 | $-0.15 | $3B | $-10.1M | -0.3% |
| 2024 | $-30.16 | $2.78B | $-2.05B | -73.7% |
| 2025 | $-16.69 | $2.73B | $-1.13B | -41.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $2.15 | $2.13 – $2.17 | $2.77B | $2.76B – $2.78B | 4 |
| 2027 | $2.91 | $2.54 – $3.29 | $2.88B | $2.85B – $2.9B | 4 |
| 2028 | $3.47 | $3.44 – $3.49 | $3B | $3B – $3.01B | 1 |
| 2029 | $3.78 | $3.74 – $3.80 | $3.09B | $3.07B – $3.1B | 1 |
| 2030 | $3.10 | $3.07 – $3.12 | $3.11B | $3.09B – $3.12B | 1 |
